We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Mindfulness Based Stress Reduction for High Blood Pressure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00440596
Recruitment Status : Completed
First Posted : February 27, 2007
Results First Posted : November 9, 2020
Last Update Posted : November 9, 2020
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Joel Hughes, Kent State University

Brief Summary:
Nearly 60 million adults in the United States have high blood pressure (BP) in the pre-hypertension (SBP 120-139 or DBP 80-89). Hypertension is estimated to account for 1 in 8 deaths in the world, and in the US the direct and indirect costs of high BP are estimated to reach $59.7 billion in 2005. JNC-7 guidelines recommend lifestyle modifications for prehypertension, followed by antihypertensive medication if BP progresses to Stage I hypertension. Mindfulness-based Stress Reduction (MBSR) is an increasingly popular practice that has been purported to alleviate stress and treat certain health conditions. Some stress management therapies and one meditation therapy (e.g., Transcendental Meditation) have shown promise in reducing elevated BP, but MBSR has not been evaluated as a treatment for high BP. When added to lifestyle modification advice, MBSR may be an appropriate complementary treatment for prehypertension. However, prior to a large randomized clinical trial of MBSR for prehypertension and/or hypertension, pilot data is necessary to provide preliminary evidence of a treatment effect and to evaluate feasibility. This feasibility randomized clinical trial of MBSR for unmedicated prehypertension will provide preliminary evidence to support a larger randomized clinical trial by evaluating the feasibility and safety of MBSR as a complementary treatment for high BP and by documenting any treatment effect. Sixty patients with unmedicated BP in the range of SBP 120-139 mm Hg or DBP 80-89 mm Hg will be randomly assigned to MBSR or a progressive muscle relaxation control condition. All patients will receive lifestyle modification advice. Patients will complete 8 weeks of MBSR delivered in a group format by an experienced psychologist trained in MBSR or 8 weeks of progressive muscle relaxation training matched for therapist contact and homework. Patients BP will be assessed prior to randomization and following treatment by researchers blind to treatment assignment. Accrual rates, acceptance of randomization, treatment adherence, treatment fidelity, and patient satisfaction with treatment will be evaluated.

Condition or disease Intervention/treatment Phase
Hypertension Behavioral: Mindfulness based stress reduction Behavioral: Progressive Muscle Relaxation Not Applicable

Detailed Description:
See brief summary

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Mindfulness Based Stress Reduction for High Blood Pressure
Study Start Date : September 2006
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Mindfulness based stress reduction
Mindfulness based stress reduction
Behavioral: Mindfulness based stress reduction
8 weeks group MBSR

Active Comparator: Progressive Muscle Relaxation
Progressive Muscle Relaxation
Behavioral: Progressive Muscle Relaxation
8 weeks PMR in group format

Primary Outcome Measures :
  1. SBP [ Time Frame: 12 weeks ]
  2. DBP [ Time Frame: 12 weeks ]
    Clinic BP

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • prehypertension
  • 30-60 years of age

Exclusion Criteria:

  • normal BP
  • hypertension
  • pregnancy
  • smoking
  • use of antihypertensive medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00440596

Layout table for location information
United States, Ohio
Summa Health System
Akron, Ohio, United States, 44304
Sponsors and Collaborators
Kent State University
National Center for Complementary and Integrative Health (NCCIH)
Layout table for investigator information
Principal Investigator: Joel W Hughes, Ph.D. Kent State University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Joel Hughes, Professor, Kent State University
ClinicalTrials.gov Identifier: NCT00440596    
Other Study ID Numbers: R21AT002698-01A2 ( U.S. NIH Grant/Contract )
First Posted: February 27, 2007    Key Record Dates
Results First Posted: November 9, 2020
Last Update Posted: November 9, 2020
Last Verified: November 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases